Table:
begin	end	state
1	30	cytoplasmic
31	56	transmembrane
57	67	non-cytoplasmic
68	85	transmembrane
86	96	cytoplasmic
97	116	transmembrane
117	121	non-cytoplasmic
122	143	transmembrane
144	161	cytoplasmic
162	181	transmembrane
182	186	non-cytoplasmic
187	209	transmembrane
210	270	cytoplasmic
271	293	transmembrane
294	308	non-cytoplasmic
309	330	transmembrane
331	338	cytoplasmic
339	360	transmembrane
361	366	non-cytoplasmic
367	393	transmembrane
394	404	cytoplasmic
405	426	transmembrane
427	429	non-cytoplasmic
430	431	transmembrane
432	435	non-cytoplasmic
436	455	transmembrane
456	472	cytoplasmic

Input:
>Pf6N2E2_883 Major myo-inositol transporter IolT
MTINSYGNTADTSAAYVSPEKHQAQRYLQKITWIATFGGLLFGFDTGVINGALLYMKDDL
GLTPFTEGLVASALLIGAMMGALFSGRLSDLKGRRRIILFLAVVFFLGALACALAPTLDV
MVAARFTLGLAVGGASVVVPAYLSEMAPSSIRGRIITRNELMIVTGQFLAFTTNATLGNL
FSDLDGVWRWMLALATLPAVALWLGMLYMPESPRWLATKGRFREGLEVLKLVREEYYAKA
EMEAITQQISNERFIKKGGWRDLSQKGARRIFLIGIGIAVTSQLTGVNSIMYFGTQILTE
AGLEQRSALIANVVNGIISIGATFVGIALLDRVGRRPMMLLGFTGTTLSLLLIGLVSVFV
DPSVTRAMLILGAMAMFLASMQGLIGPAFWVLLAEIFPMRIRGGCMGMAIAAFWLTNVMI
GMFFPSLVAMIGIGQTFFVFVGAGLLSLTFVAVWVPETRGSTLEEIEQRLYG

Or try the official Phobius web server, which has a different display

Reference: Advantages of combined transmembrane topology and signal peptide prediction - the Phobius web server